Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
Status:
Withdrawn
Trial end date:
2018-10-15
Target enrollment:
Participant gender:
Summary
This study involves a course of radiation to up to 5 tumors in the participant's liver
followed by systemic therapy. (Treatment using substances that travel through the
bloodstream, reaching and affecting cells all over the body.) The type of radiation is called
stereotactic body radiation therapy (SBRT). The purpose of this study is to compare the
effects, good and/or bad, of different doses of SBRT given along with the systemic therapies,
sorafenib and bavituximab. The researchers want to see which dose of radiation will work best
in stimulating the immune response and provide local control to the participant's liver. The
usual treatment for hepatocellular carcinoma that is unresectable can be transarterial
therapy, sorafenib alone and/or clinical trial.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute